Satoru Kitazono

2.8k total citations
92 papers, 1.5k citations indexed

About

Satoru Kitazono is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Satoru Kitazono has authored 92 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in Satoru Kitazono's work include Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (36 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Satoru Kitazono is often cited by papers focused on Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (36 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Satoru Kitazono collaborates with scholars based in Japan, United States and Germany. Satoru Kitazono's co-authors include Noriko Yanagitani, Makoto Nishio, Noboru Yamamoto, Atsushi Horiike, Yutaka Fujiwara, Hiroshi Nokihara, Tomohide Tamura, Ryo Ariyasu, Ken Uchibori and Hidehito Horinouchi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Satoru Kitazono

87 papers receiving 1.4k citations

Peers

Countries citing papers authored by Satoru Kitazono

Since Specialization

Citations

This map shows the geographic impact of Satoru Kitazono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoru Kitazono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoru Kitazono more than expected).

Fields of papers citing papers by Satoru Kitazono

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoru Kitazono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoru Kitazono. The network helps show where Satoru Kitazono may publish in the future.

Co-authorship network of co-authors of Satoru Kitazono

This figure shows the co-authorship network connecting the top 25 collaborators of Satoru Kitazono. A scholar is included among the top collaborators of Satoru Kitazono based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoru Kitazono. Satoru Kitazono is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion 2024 ·Thoracic Cancer ·(unknown), (unknown), Ken Uchibori, Takahiro Akita, (unknown), (unknown), (unknown), (unknown), Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio	1
2	Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers 2024 ·Thoracic Cancer ·Takahiro Akita, Ryo Ariyasu, (unknown), (unknown), (unknown), (unknown), (unknown), Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio	2
3	High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group) 2024 ·Japanese Journal of Clinical Oncology ·Kageaki Watanabe, Keita Sasaki, Ryunosuke Machida, (unknown), Yuki Yamane, Motohiro Tamiya, Shin Saito, (unknown), Kiyotaka Yoh, Hiroshige Yoshioka, Haruyasu Murakami, Satoru Kitazono, Yasuhiro Gotô, Hidehito Horinouchi, Yuichiro Ohe	3
4	Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors 2023 ·JTO Clinical and Research Reports ·Ryo Ariyasu, (unknown), (unknown), Takahiro Akita, (unknown), (unknown), (unknown), Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio	4
5	LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study 2023 ·Annals of Oncology ·N. Girard, K. Park, Kun Tang, Byoung Chul Cho, Luis Paz‐Ares, Sunfa Cheng, Satoru Kitazono, (unknown), (unknown), Joshua K. Sabari, Rachel E. Sanborn, Aaron S. Mansfield, J-Y. Hung, Sanjay Popat, Josiane Mourão Dias, (unknown), (unknown), (unknown), Roland E. Knoblauch, Caicun Zhou	5
6	552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) 2023 ·Annals of Oncology ·M-J. Ahn, Byoung Chul Cho, Yasushi Goto, Kiyotaka Yoh, Wu‐Chou Su, Junichi Shimizu, Jin Sun Lee, Satoshi Oizumi, (unknown), Hidetoshi Hayashi, Hong Zebger‐Gong, (unknown), Lei Lan, (unknown), Satoru Kitazono	4
7	Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight 2023 ·Cancer Science ·Yutaka Fujiwara, (unknown), Tetsunari Hase, Naozumi Hashimoto, Tomoyuki Naito, Yukari Tsubata, (unknown), Toshiaki Takahashi, Haruki Kobayashi, Yuki Shinno, Yoshitaka Zenke, Takaya Ikeda, Yukio Hosomi, Kageaki Watanabe, Satoru Kitazono, (unknown), Yoshinori Makino, Noboru Yamamoto	7
8	518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) 2023 ·Annals of Oncology ·Satoru Kitazono, Luis Paz‐Ares, M-J. Ahn, Aaron Lisberg, Byoung Chul Cho, George R. Blumenschein, Elaine Shum, (unknown), Yasushi Goto, Kiyotaka Yoh, Rebecca S. Heist, Paul Baas, David Planchard, M. Pérol, Enriqueta Felip, Wu‐Chou Su, Hong Zebger‐Gong, Lei Lan, (unknown), Jacob Sands	8
9	Clinical characteristics of patients with KRAS mutation detected by liquid biopsy 2023 ·Thoracic Cancer ·(unknown), Siew‐Kee Low, Hironori Ninomiya, (unknown), (unknown), (unknown), Takahiro Akita, (unknown), Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio	2
10	LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01 2023 ·Annals of Oncology ·M-J. Ahn, Aaron Lisberg, Luis Paz‐Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons‐Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, M. Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Jacob Sands, Richard D. Hall, Yong Zhang, Hong Zebger‐Gong, (unknown), Isamu Okamoto	34
11	First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01 2023 ·Journal of Clinical Oncology ·Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, Alexander I. Spira, Edward B. Garon, Satoru Kitazono, Melissa L. Johnson, Funda Meric‐Bernstam, Anthony W. Tolcher, Noboru Yamamoto, Jon Greenberg, Yui Kawasaki, Hong Zebger‐Gong, Fumiaki Kobayashi, Penny Phillips, Aaron Lisberg, Rebecca S. Heist	76
12	Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity 2021 ·npj Precision Oncology ·Takahiro Yoshizawa, Ken Uchibori, Mitsugu Araki, Shigeyuki Matsumoto, Biao Ma, Ryo Kanada, Yosuke Seto, Tomoko Oh‐hara, Sumie Koike, Ryo Ariyasu, Satoru Kitazono, Hironori Ninomiya, Kengo Takeuchi, Noriko Yanagitani, Satoshi Takagi, Kazuma Kishi, Naoya Fujita, Yasushi Okuno, Makoto Nishio, Ryohei Katayama	16
13	Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR 2021 ·Cancer Science ·Ryo Ariyasu, Ken Uchibori, Takaaki Sasaki, (unknown), Kazuma Kiyotani, Ryohei Yoshida, Yusuke Ono, Satoru Kitazono, Hironori Ninomiya, Yuichi Ishikawa, Yusuke Mizukami, Noriko Yanagitani, Naoya Fujita, Makoto Nishio, Ryohei Katayama	8
14	Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib 2021 ·Cancer Reports ·Hiroaki Sakamoto, Noriko Yanagitani, (unknown), (unknown), (unknown), Takehiro Tozuka, Hiroshi Yoshida, (unknown), Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Sadatomo Tasaka, Makoto Nishio	2
15	Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2 2021 ·Thoracic Cancer ·Ken Uchibori, (unknown), (unknown), (unknown), (unknown), Takehiro Tozuka, Hiroaki Sakamoto, Hiroshi Yoshida, (unknown), Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio	4
16	Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma 2020 ·Cancer Medicine ·Yusuke Okuma, Yasushi Goto, Fumiyoshi Ohyanagi, Kuniko Sunami, Yoshiro Nakahara, Satoru Kitazono, Keita Kudo, Yuichi Tambo, Shintaro Kanda, Noriko Yanagitani, Atsushi Horiike, Hidehito Horinouchi, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Makoto Nishio, Yuichiro Ohe, Yukio Hosomi	14
17	Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice 2020 ·Thoracic Cancer ·Ryo Ariyasu, Ken Uchibori, Hironori Ninomiya, (unknown), (unknown), (unknown), (unknown), Takehiro Tozuka, Hiroshi Yoshida, (unknown), Satoru Kitazono, Noriko Yanagitani, Kengo Takeuchi, Makoto Nishio	15
18	Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms 2020 ·Cancer Science ·Noriko Yanagitani, Ken Uchibori, Sumie Koike, (unknown), Satoru Kitazono, Takahiro Yoshizawa, Atsushi Horiike, Fumiyoshi Ohyanagi, Yuichi Tambo, Shingo Nishikawa, Naoya Fujita, Ryohei Katayama, Makoto Nishio	41
19	Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms 2020 ·Cancer Chemotherapy and Pharmacology ·Ryo Ariyasu, Noriko Yanagitani, (unknown), Toshikazu Yamaguchi, Ken Uchibori, Satoru Kitazono, Naoya Fujita, Ryohei Katayama, Makoto Nishio	3
20	Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody 2019 ·Lung Cancer ·(unknown), Takahiro Yoshizawa, (unknown), Ryo Ariyasu, Junji Koyama, (unknown), Ken Uchibori, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Makoto Nishio	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact